Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alto Neuroscience, Inc.ANRO · Entity 4755 | Director | May 12, 2026 | May 14, 2026 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alto Neuroscience, Inc.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.63 · Expires 2036-05-11 | Direct | 10,958 |
Reported balance
After 2026-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 10,958 · Balance 10,958 F2: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. F1: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.
F2: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 1
1 source rowRow 1 · 2024-08-01 · Disposition to issuer · Disposed 14,673 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-01 · Disposition to issuer · Disposed 1,393,153 · Balance 0 F2: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 87,573 · Balance 0 F3: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
F3: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 10, 2026 21:23 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 15,200 | $0.00 Strike: $35.21 | $0.00 |
DisclosureSEC source: 0001193125-26-266080 · ownership.xml · derivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,200 Underlying: Common Stock · 15,200 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:00 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 10,958 | $0.00 Strike: $24.63 | $0.00 |
DisclosureSEC source: 0001830326-26-000005 · wk-form4_1778792418.xml · derivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,958 Underlying: Common Stock · 10,958 shares Expires 2036-05-11 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:45 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 3,806 | $11.82 Strike: $16.59 | $44,986.92 |
DisclosureSEC source: 0001830326-26-000002 · wk-form4_1767735946.xml · derivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,806 Underlying: Common Stock · 3,806 shares Expires 2036-01-01 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $45,000. F1 · derivative.exercise_date: 952 shares underlying the option shall vest on March 31, 2026, 951 shares underlying the option shall vest on June 30, 2026, 952 shares underlying the option shall vest on September 30, 2026 and 951 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 21:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 3,928 | $2.21 Strike: $3.18 | $8,680.88 |
DisclosureSEC source: 0001999480-25-000081 · wk-form4_1755206542.xml · derivative · entry 2 Sanchez Ramiro · CIK 0001830326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,928 Underlying: Common Stock · 3,928 shares Expires 2035-08-11 F4 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $8,682.07. F3 · derivative.exercise_date: 1,383 shares underlying the option shall vest on September 30, 2025, and 2,545 shares underlying the option shall vest on December 31, 2025, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 21:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 30,574 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001999480-25-000081 · wk-form4_1755206542.xml · derivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,574 Underlying: Common Stock · 30,574 shares Expires 2035-08-11 F2 · price: The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F1 · derivative.exercise_date: The shares underlying the option shall vest in 36 equal monthly installments commencing on September 12, 2025, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:15 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 10,925 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0000950170-25-087904 · ownership.xml · derivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,925 Underlying: Common Stock · 10,925 shares Expires 2035-06-17 F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 17, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| November 07, 2024 Filed Nov 7, 2024 23:47 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 29,756 | $0.00 Strike: $26.90 | $0.00 |
DisclosureSEC source: 0000950170-24-123600 · ownership.xml · derivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,756 Underlying: Common Stock · 29,756 shares Expires 2034-11-07 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on November 7, 2025, with the remaining shares vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:38 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerRestricted Stock Units · Derivative | 87,573 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-090861 · ownership.xml · derivative · entry 3 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,573 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:38 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,393,153 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090861 · ownership.xml · derivative · entry 2 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,393,153 shares Expires not disclosed F2 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F2 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F2 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F2 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:38 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 14,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090861 · ownership.xml · nonDerivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 17:34 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 87,573 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-006671 · ownership.xml · derivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,573 Underlying: Common Stock · 87,573 shares Expires not disclosed F1 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.exercise_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.expiration_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-23-073591 · ownership.xml · derivative · entry 3 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 538,435 Underlying: Common Stock · 10,000 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 10,000 | $42.47 | $424,700.00 |
DisclosureSEC source: 0000950170-23-073591 · ownership.xml · nonDerivative · entry 2 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,673 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 10,000 | $3.50 | $35,000.00 |
DisclosureSEC source: 0000950170-23-073591 · ownership.xml · nonDerivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 20:14 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 10,152 | $41.42 | $420,528.33 |
DisclosureSEC source: 0000950170-23-072370 · ownership.xml · nonDerivative · entry 2 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,673 F3 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.36 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 20:14 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionRestricted Stock Units · Derivative | 24,825 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-072370 · ownership.xml · derivative · entry 3 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represented the contingent right to receive one share of the Issuer's common stock. F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F1 · derivative.exercise_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F1 · derivative.expiration_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 20:14 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 24,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-072370 · ownership.xml · nonDerivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F2 · price: Each RSU represented the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0000950170-23-071490 · ownership.xml · derivative · entry 3 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,390 Underlying: Common Stock · 7,500 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 50% of the shares subject to this option vested and became exercisable on October 28, 2022, with the remainder vesting in two (2) equal annual installments thereafter. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 7,500 | $41.39 | $310,392.75 |
DisclosureSEC source: 0000950170-23-071490 · ownership.xml · nonDerivative · entry 2 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.385 to $41.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 7,500 | $9.88 | $74,100.00 |
DisclosureSEC source: 0000950170-23-071490 · ownership.xml · nonDerivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 16:17 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-23-069417 · ownership.xml · derivative · entry 3 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 548,435 Underlying: Common Stock · 10,000 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on January 14, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 16:17 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 10,000 | $41.37 | $413,700.00 |
DisclosureSEC source: 0000950170-23-069417 · ownership.xml · nonDerivative · entry 2 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 16:17 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 10,000 | $3.50 | $35,000.00 |
DisclosureSEC source: 0000950170-23-069417 · ownership.xml · nonDerivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 20:25 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 24,825 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004357 · doc4.xml · derivative · entry 2 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,825 Underlying: Common Stock · 24,825 shares Expires not disclosed F2 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 20:25 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 97,691 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0000899243-23-004357 · doc4.xml · derivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,691 Underlying: Common Stock · 97,691 shares Expires 2033-02-06 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:43 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 168,856 | $0.00 Strike: $30.36 | $0.00 |
DisclosureSEC source: 0000899243-22-005934 · doc4.xml · derivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,856 Underlying: Common Stock · 168,856 shares Expires 2032-02-09 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 18:56 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 278,637 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000899243-21-005105 · doc4.xml · derivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,637 Underlying: Common Stock · 278,637 shares Expires 2031-02-03 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 3, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| October 28, 2020 Filed Oct 30, 2020 20:18 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 130,890 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0000899243-20-030032 · doc4.xml · derivative · entry 1 Sanchez Ramiro · CIK 0001830326 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,890 Underlying: Common Stock · 130,890 shares Expires 2030-10-28 F1 · derivative.exercise_date: 50% of this option shall vest and become exercisable on October 28, 2022, with the remainder vesting in two (2) equal annual installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.